PepGen pauses UK arm of DMD trial that's already on hold in US
While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy therapy in the U.S., the biotech has decided to pause the U.K. arm of the study.
While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy therapy in the U.S., the biotech has decided to pause the U.K. arm of the study.
